MCID: ADN016
MIFTS: 64

Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Adenocarcinoma

MalaCards integrated aliases for Adenocarcinoma:

Name: Adenocarcinoma 11 28 53 5 43 14 16 71 75
Adenocarcinoma and Carcinoid Combined of Unspecified Site 33
Adenocarcinoid Tumour of Unspecified Site 33
Adenoacanthoma of Unspecified Site 33
Adenocarcinoid of Unspecified Site 33
Adenocarcinoma Nos 33
Adenocarcinomas 14

Classifications:



External Ids:

Disease Ontology 11 DOID:299
MeSH 43 D000230
NCIt 49 C2852
SNOMED-CT 68 35917007
ICD11 33 1979211198
UMLS 71 C0001418

Summaries for Adenocarcinoma

Disease Ontology: 11 A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary: Adenocarcinoma, also known as adenocarcinoma and carcinoid combined of unspecified site, is related to pancreatic adenocarcinoma and appendix adenocarcinoma. An important gene associated with Adenocarcinoma is H19 (H19 Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are Gene expression (Transcription) and Disease. The drugs Iron isomaltoside 1000 and Rabeprazole have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and pancreas, and related phenotypes are Decreased viability and Decreased viability

Wikipedia: 75 Adenocarcinoma (/ˌædɪnoʊkɑːrsɪˈnoʊmə/; plural adenocarcinomas or adenocarcinomata... more...

Related Diseases for Adenocarcinoma

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2914)
# Related Disease Score Top Affiliating Genes
1 pancreatic adenocarcinoma 33.4 TP53 TGFBR2 SMAD4 PIK3CA KRAS ERBB2
2 appendix adenocarcinoma 33.4 TP53 SMAD4 KRAS
3 small intestine adenocarcinoma 33.3 TP53 SMAD4 KRAS
4 endometrial adenocarcinoma 33.3 TP53 KRAS EGFR CDKN2A AKT1
5 mucinous adenocarcinoma 33.3 TP53 SMAD4 PIK3CA MUC1 KRAS ERBB2
6 adenocarcinoma in situ 33.2 TP53 KRAS EGFR CDKN2A
7 colon adenocarcinoma 33.2 TP53 SMAD4 PIK3CA KRAS EGFR CDH1
8 barrett esophagus 33.2 TP53 SMAD4 ERBB2 CDKN2A APC
9 papillary adenocarcinoma 33.2 TP53 MUC1 KRAS ERBB2
10 suppression of tumorigenicity 12 33.1 TP53 SMAD4 PIK3CA ERBB2 EGFR CDKN2A
11 cervical adenocarcinoma 33.1 TP53 KRAS CDKN2A BRAF
12 apocrine adenocarcinoma 33.1 TP53 PIK3CA ERBB2 EGFR
13 ovary adenocarcinoma 33.1 TP53 PIK3CA MUC1 KRAS ERBB2 EGFR
14 rectum adenocarcinoma 33.0 TP53 SMAD4 PIK3CA KRAS ERBB2 EGFR
15 gastric adenocarcinoma 33.0 TP53 SMAD4 PIK3CA KRAS H19 ERBB2
16 colorectal adenocarcinoma 33.0 TP53 SMAD4 PIK3CA KRAS ERBB2 EGFR
17 bronchiolo-alveolar adenocarcinoma 33.0 TP53 KRAS EGFR CDH1
18 pancreatic ductal adenocarcinoma 32.9 TP53 SMAD4 KRAS H19
19 tubular adenocarcinoma 32.9 MUC1 ERBB2 CDH1
20 signet ring cell adenocarcinoma 32.9 TP53 MUC1 KRAS ERBB2 CDH1
21 barrett's adenocarcinoma 32.9 TP53 ERBB2 CDKN2A
22 ampulla of vater adenocarcinoma 32.9 SMAD4 MUC1 KRAS
23 gallbladder adenocarcinoma 32.8 TP53 MUC1 ERBB2
24 endometrial mucinous adenocarcinoma 32.8 KRAS CDKN2A
25 scirrhous adenocarcinoma 32.8 ERBB2 CDH1
26 breast adenocarcinoma 32.8 TP53 PIK3CA MUC1 KRAS H19 ERBB2
27 esophagus adenocarcinoma 32.8 TP53 HNF1A-AS1 ERBB2 EGFR CDKN2A CDH1
28 gastroesophageal junction adenocarcinoma 32.8 TP53 ERBB2 EGFR
29 gastroesophageal adenocarcinoma 32.8 TP53 PIK3CA KRAS ERBB2 EGFR AKT1
30 papillary serous adenocarcinoma 32.7 TP53 KRAS ERBB2
31 lung cancer susceptibility 3 32.7 TP53 TGFBR2 SMAD4 RB1 PIK3CA MUC1
32 renal cell carcinoma, papillary, 1 32.7 TP53 PIK3CA KRAS ERBB2 EGFR CDKN2A
33 endocervical adenocarcinoma 32.7 TP53 SMAD4 PIK3CA ERBB2 CDKN2A
34 adenosquamous carcinoma 32.7 MUC1 KRAS EGFR
35 sebaceous adenocarcinoma 32.7 TP53 ERBB2 CDKN2A
36 endometrial serous adenocarcinoma 32.7 TP53 PIK3CA KRAS ERBB2 ATM
37 thyroid gland follicular carcinoma 32.6 TP53 PIK3CA CDH1 BRAF AKT1
38 serous cystadenocarcinoma 32.6 TP53 PIK3CA KRAS ERBB2 CDKN2A CDH1
39 esophageal cancer 32.6 TP53 TGFBR2 SMAD4 RB1 PIK3CA KRAS
40 diffuse gastric cancer 32.6 TP53 TGFBR2 SMAD4 KRAS ERBB2 CDH1
41 vaginal cancer 32.6 TP53 EGFR CDKN2A
42 diffuse gastric and lobular breast cancer syndrome 32.6 TP53 SMAD4 PIK3CA KRAS ERBB2 EPCAM
43 inflammatory breast carcinoma 32.5 ERBB2 EGFR CDH1
44 bile duct adenocarcinoma 32.5 TP53 KRAS EGFR CDH1 AKT1
45 adenoid cystic carcinoma 32.4 TP53 PIK3CA MUC1 KRAS ERBB2 EGFR
46 chromophobe renal cell carcinoma 32.4 TP53 PIK3CA ERBB2 EGFR CDH1 AKT1
47 colorectal adenoma 32.4 TP53 SMAD4 KRAS EGFR CDH1 APC
48 pancreatic foamy gland adenocarcinoma 32.3 TP53 MUC1
49 pulmonary adenocarcinoma in situ 32.3 TP53 KRAS EGFR
50 cystadenocarcinoma 32.3 TP53 MUC1 KRAS BIRC5 AKT1

Graphical network of the top 20 diseases related to Adenocarcinoma:



Diseases related to Adenocarcinoma

Symptoms & Phenotypes for Adenocarcinoma

GenomeRNAi Phenotypes related to Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.16 BRAF EGFR KRAS MUC1 PIK3CA
2 Decreased viability GR00055-A-2 11.16 BRAF EGFR KRAS MUC1 PIK3CA
3 Decreased viability GR00055-A-3 11.16 KRAS
4 Decreased viability GR00106-A-0 11.16 KRAS
5 Decreased viability GR00107-A-1 11.16 TGFBR2
6 Decreased viability GR00221-A-1 11.16 AKT1 CDKN2A TGFBR2 EGFR KRAS PIK3CA
7 Decreased viability GR00221-A-2 11.16 AKT1 KRAS PIK3CA
8 Decreased viability GR00221-A-3 11.16 AKT1 ATM CDKN2A ERBB2 TGFBR2
9 Decreased viability GR00221-A-4 11.16 AKT1 ATM CDKN2A ERBB2 TGFBR2 BRAF
10 Decreased viability GR00249-S 11.16 AKT1 TGFBR2 BRAF MUC1
11 Decreased viability GR00301-A 11.16 BRAF KRAS CDH1
12 Decreased viability GR00381-A-1 11.16 BRAF KRAS
13 Decreased viability GR00402-S-2 11.16 TGFBR2 PIK3CA CDH1
14 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.32 AKT1 BIRC5 CDKN2A RB1
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.32 AKT1 ATM BAX BIRC5 BRAF CDKN2A
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 10.32 ATM BAX TP53
17 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.93 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.93 APC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.93 BRAF
20 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.93 RB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.93 RB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-181 9.93 RB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.93 APC
24 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.93 APC
25 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.93 RB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.93 AKT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.93 KRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.93 RB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.93 BRAF
30 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.93 RB1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.93 AKT1 PIK3CA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.93 KRAS
33 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.93 AKT1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.93 AKT1
35 Increased cell viability after pRB stimulation GR00230-A-1 9.62 AKT1 EGFR ERBB2 TGFBR2
36 Decreased viability after gemcitabine stimulation GR00107-A-2 9.54 ATM CDKN2A TGFBR2
37 Decreased viability in pancreas lineage GR00235-A 9.26 TGFBR2 TP53
38 Reduced mammosphere formation GR00396-S 9.23 ATM BIRC5 BRAF CDH1 EGFR H19

MGI Mouse Phenotypes related to Adenocarcinoma:

45 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.54 AKT1 APC ATM BAX BRAF CDH1
2 homeostasis/metabolism MP:0005376 10.53 AKT1 APC ATM BAX BIRC5 BRAF
3 endocrine/exocrine gland MP:0005379 10.5 AKT1 APC ATM BAX BIRC5 BRAF
4 nervous system MP:0003631 10.49 AKT1 APC ATM BAX BRAF CDKN2A
5 growth/size/body region MP:0005378 10.46 AKT1 APC ATM BAX BRAF CDH1
6 normal MP:0002873 10.44 AKT1 APC BIRC5 BRAF CDH1 EGFR
7 embryo MP:0005380 10.44 AKT1 APC ATM BIRC5 BRAF CDH1
8 muscle MP:0005369 10.42 AKT1 APC BAX BRAF CDKN2A EGFR
9 cellular MP:0005384 10.42 AKT1 APC ATM BAX BIRC5 BRAF
10 digestive/alimentary MP:0005381 10.37 APC BRAF CDH1 CDKN2A EGFR EPCAM
11 cardiovascular system MP:0005385 10.35 AKT1 APC ATM BRAF CDH1 CDKN2A
12 liver/biliary system MP:0005370 10.34 AKT1 APC BRAF CDKN2A EGFR KRAS
13 immune system MP:0005387 10.34 AKT1 APC ATM BAX BIRC5 BRAF
14 behavior/neurological MP:0005386 10.3 AKT1 APC ATM BAX BRAF CDKN2A
15 no phenotypic analysis MP:0003012 10.28 CDH1 CDKN2A EGFR EPCAM KRAS MUC1
16 renal/urinary system MP:0005367 10.26 APC BAX BRAF EGFR KRAS RB1
17 pigmentation MP:0001186 10.24 APC BRAF CDKN2A EGFR KRAS RB1
18 limbs/digits/tail MP:0005371 10.24 APC BAX BRAF EGFR ERBB2 KRAS
19 adipose tissue MP:0005375 10.24 AKT1 APC ATM BRAF EGFR PIK3CA
20 reproductive system MP:0005389 10.21 AKT1 APC ATM BAX BRAF CDH1
21 craniofacial MP:0005382 10.16 APC BRAF EGFR ERBB2 KRAS RB1
22 skeleton MP:0005390 10.13 AKT1 APC BAX BRAF CDKN2A EGFR
23 hearing/vestibular/ear MP:0005377 10.11 APC BAX BRAF EGFR KRAS RB1
24 respiratory system MP:0005388 10.1 AKT1 BAX BRAF CDKN2A EGFR ERBB2
25 hematopoietic system MP:0005397 10.03 AKT1 APC ATM BAX BIRC5 BRAF
26 vision/eye MP:0005391 10 APC BAX BRAF CDKN2A EGFR KRAS
27 mortality/aging MP:0010768 9.89 AKT1 APC ATM BAX BIRC5 BRAF
28 integument MP:0010771 9.5 AKT1 APC ATM BRAF CDH1 CDKN2A

Drugs & Therapeutics for Adenocarcinoma

Drugs for Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 737)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
2
Rabeprazole Approved, Investigational Phase 4 117976-89-3, 117976-90-6 5029
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4
Desflurane Approved Phase 4 57041-67-5 42113
5
Prilocaine Approved Phase 4 721-50-6 4906
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
8
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
9
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
10
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
11
Framycetin Approved, Experimental, Vet_approved Phase 4 1404-04-2, 3947-65-7, 119-04-0 413349 8378
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
14
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
15
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
17
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
18
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
19 Endostar protein Phase 4
20 Adrenergic Agents Phase 4
21 Anesthetics Phase 4
22 Hepcidins Phase 4
23 Cholinergic Agents Phase 4
24 Anesthetics, Local Phase 4
25 Hypnotics and Sedatives Phase 4
26 Anesthetics, General Phase 4
27 Anesthetics, Inhalation Phase 4
28 Sodium Channel Blockers Phase 4
29 Diuretics, Potassium Sparing Phase 4
30 Muscarinic Antagonists Phase 4
31 Cholinergic Antagonists Phase 4
32 Adrenergic alpha-Agonists Phase 4
33 Adrenergic Agonists Phase 4
34 Anesthetics, Intravenous Phase 4
35 Excitatory Amino Acid Antagonists Phase 4
36 Anesthetics, Dissociative Phase 4
37
Methylprednisolone Acetate Phase 4 584547
38
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2
39
Medroxyprogesterone acetate Approved, Investigational Phase 3 520-85-4, 71-58-9 10631 6279
40
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
41
Chlorpheniramine Approved Phase 3 113-92-8, 132-22-9 2725
42
Ranitidine Approved, Withdrawn Phase 3 66357-59-3, 82530-72-1, 66357-35-5 3001055 5039
43
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
44
Rosiglitazone Approved, Investigational Phase 3 122320-73-4, 155141-29-0 77999
45
Vinblastine Approved Phase 3 865-21-4 241903 13342
46
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
47
Estramustine Approved, Investigational Phase 3 2998-57-4 259331
48
Cyproterone acetate Approved, Investigational Phase 3 427-51-0 9880
49
Venlafaxine Approved Phase 3 99300-78-4, 93413-69-5 5656
50
Norepinephrine Approved Phase 3 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 3572)
# Name Status NCT ID Phase Drugs
1 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
2 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
3 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
4 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy
5 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
6 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
7 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
8 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
9 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
10 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
11 An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
12 Clinical Outcomes of Endoscopic Resection for Treating Extremely Well Differentiated Intestinal-type Adenocarcinoma (WHYX Lesion) Completed NCT01451034 Phase 4
13 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
14 A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
15 Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study Completed NCT02426034 Phase 4 ApatinibTablets
16 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
17 Prospective Randomized Study of Single Incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer Completed NCT01579721 Phase 4
18 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel;periprostatic nerve blockade
19 A Multicenter Phase 4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Completed NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
20 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
21 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
22 A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy ) Completed NCT01661166 Phase 4 Fesoterodine;Placebo oral tablet
23 Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy Completed NCT03164590 Phase 4 Ketamine;dexmedetomidine;bupivacaine
24 PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
25 Association of HSD3B1 Genotype With Response to Preoperative Letrozole Therapy Among Postmenopausal Women With Estrogen-Receptor Positive (ER+) HER2/Neu-Negative (HER2-) Invasive Carcinomas of the Breast Recruiting NCT05183828 Phase 4 Letrozole
26 PAXG Out in the Country Recruiting NCT04480268 Phase 4 PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy
27 Synergistic Real-World Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors(TKIs)in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): Prospective Study Recruiting NCT04401059 Phase 4 Elemene plus first or third generation EGFR-TKIs;First or third generation EGFR-TKIs
28 Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery - a Prospective, Randomized Controlled Trial Recruiting NCT04281667 Phase 4 Oral Antibiotics;Placebo;Mechanical Bowel Preparation
29 Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Doubleblind, Placebo-controlled, Multicentre Trial. Not yet recruiting NCT02004782 Phase 4 Prednisolone;Placebo Oral Tablet
30 Reduction in Symptomatic Esophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Double-blinded, Placebo-controlled, Multicenter Trial. Terminated NCT02039115 Phase 4 prednisone;placebo
31 A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL Cancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy Terminated NCT00536107 Phase 4 Gefitinib;Docetaxel
32 A Pharmacokinetic Study of Capecitabine in Patients Undergoing Peri-operative Chemotherapy and a Total Gastrectomy for Adenocarcinoma of the Stomach Terminated NCT00871273 Phase 4 capecitabine
33 Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy Terminated NCT01365143 Phase 4
34 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn NCT03891979 Phase 4 Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
35 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
36 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
37 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
38 Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Unknown status NCT02628665 Phase 3 photosensitizer(photofrin)
39 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Unknown status NCT02011997 Phase 3
40 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
41 Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation Unknown status NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo
42 A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma Unknown status NCT02281708 Phase 3 vinorelbine plus cisplatin
43 Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma Unknown status NCT02518802 Phase 3 Gefitinib;Pemetrexed
44 A Randomized Multicenter Phase III Study:Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone vs.Taxanes or Platinum Combined With Capecitabine in Advanced Adenocarcinoma of the Stomach or Esophagogastric Junction. Unknown status NCT01468389 Phase 3 Capecitabine;capecitabine
45 Efficacy and Safety Study of the Combined Modality Therapy in Patients With Potentially Resectable, Locally Advanced Adenocarcinoma of the Esophago-gastric Junction With Preoperative Chemo- and Chemoradiation Followed by Surgical Resection Unknown status NCT01523015 Phase 2, Phase 3
46 Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
47 Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study Unknown status NCT02125240 Phase 3 Icotinib;Placebo
48 Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
49 A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen Unknown status NCT00088660 Phase 3
50 Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial Unknown status NCT02780921 Phase 3

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thiotepa

Cochrane evidence based reviews: adenocarcinoma

Genetic Tests for Adenocarcinoma

Genetic tests related to Adenocarcinoma:

# Genetic test Affiliating Genes
1 Adenocarcinoma 28

Anatomical Context for Adenocarcinoma

Organs/tissues related to Adenocarcinoma:

MalaCards : Lung, Prostate, Pancreas, Lymph Node, Breast, Colon, T Cells

Publications for Adenocarcinoma

Articles related to Adenocarcinoma:

(show top 50) (show all 58252)
# Title Authors PMID Year
1
Role of CDK8 and beta-catenin in colorectal adenocarcinoma. 53 62
20514474 2010
2
Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. 53 62
19892429 2010
3
A novel clinically relevant animal model for studying galectin-3 and its ligands during colon carcinogenesis. 53 62
20197492 2010
4
HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. 53 62
20347035 2010
5
Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. 53 62
19949912 2010
6
Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. 53 62
19716197 2010
7
Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus. 53 62
20518902 2010
8
Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. 53 62
19415536 2010
9
The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. 53 62
20339853 2010
10
Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. 53 62
20372850 2010
11
Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. 53 62
19856421 2010
12
Identification of gastrointestinal contamination in endoscopic ultrasound-guided pancreatic fine needle aspiration. 53 62
20518405 2010
13
Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types. 53 62
20038908 2010
14
Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis? 53 62
20182859 2010
15
The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. 53 62
20190734 2010
16
Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions. 53 62
20518411 2010
17
True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. 53 62
20407331 2010
18
MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain. 53 62
20090516 2010
19
DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines. 53 62
20372780 2010
20
Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells. 53 62
20213678 2010
21
A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. 53 62
20173733 2010
22
Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. 53 62
20439191 2010
23
Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor. 53 62
20004952 2010
24
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. 53 62
20146302 2010
25
Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. 53 62
20377670 2010
26
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. 53 62
20154720 2010
27
Diagnostic value and implications of vimentin expression in normal, reactive and neoplastic endocervical epithelium. 53 62
20350213 2010
28
Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. 53 62
20062011 2010
29
Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). 53 62
20350215 2010
30
Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas. 53 62
19280218 2010
31
Lymph node involvement and not the histophatologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. 53 62
20107918 2010
32
Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. 53 62
20040392 2010
33
Significance of mucin expression in pancreatobiliary neoplasms. 53 62
19787286 2010
34
Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. 53 62
20158339 2010
35
Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study. 53 62
19935673 2010
36
Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. 53 62
19875957 2010
37
Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. 53 62
20183914 2010
38
Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. 53 62
20193080 2010
39
Comparison of osteopontin, beta-catenin and hnRNP B1 expression in lung carcinomas. 53 62
19609729 2010
40
CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. 53 62
19926591 2010
41
Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas. 53 62
20515563 2010
42
Integration of biomarkers including molecular targeted therapies in head and neck cancer. 53 62
20237991 2010
43
Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications. 53 62
20108111 2010
44
Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? 53 62
20087229 2010
45
SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. 53 62
20393008 2010
46
Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. 53 62
20074157 2010
47
Tumor expression of integrin-linked kinase (ILK) correlates with the expression of the E-cadherin repressor snail: an immunohistochemical study in ductal pancreatic adenocarcinoma. 53 62
20091050 2010
48
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. 53 62
20233436 2010
49
The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears. 53 62
19744186 2010
50
PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. 53 62
20061933 2010

Variations for Adenocarcinoma

ClinVar genetic disease variations for Adenocarcinoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Likely Pathogenic
12365 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
2 ATM, C11orf65 NM_000051.4(ATM):c.6095G>A (p.Arg2032Lys) SNV Likely Pathogenic
181974 rs139770721 GRCh37: 11:108186638-108186638
GRCh38: 11:108315911-108315911

Copy number variations for Adenocarcinoma from CNVD:

6 (show all 49)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 25149 1 184907591 184916179 Amplification PTGS2 Adenocarcinoma
2 33704 1 47467454 47552406 Amplification STIL Adenocarcinoma
3 66093 12 25249446 25295130 Amplification KRAS Adenocarcinoma
4 66576 12 3100000 5300000 Gain Adenocarcinoma
5 66578 12 3100000 5300000 Gain Adenocarcinoma
6 66580 12 3100000 5300000 Gain TSPAN9 Adenocarcinoma
7 74649 13 109973413 110012072 Amplification RAB20 Adenocarcinoma
8 87573 14 74815283 74818665 Amplification FOS Adenocarcinoma
9 93655 15 57100000 61500000 Loss RORA Adenocarcinoma
10 95696 15 79500000 83000000 Loss DNM1P41 Adenocarcinoma
11 95698 15 79500000 83000000 Loss Adenocarcinoma
12 95700 15 79500000 83000000 Loss Adenocarcinoma
13 95702 15 79500000 83000000 Loss Adenocarcinoma
14 95704 15 79500000 83000000 Loss Adenocarcinoma
15 95706 15 79500000 83000000 Loss LOC440300 Adenocarcinoma
16 95708 15 79500000 83000000 Loss Adenocarcinoma
17 97921 16 14700000 16700000 Loss Adenocarcinoma
18 107538 17 15900000 22100000 Loss Adenocarcinoma
19 111139 17 35097918 35138441 Amplification ERBB2 Adenocarcinoma
20 123836 18 89115825 89123587 Amplification SPP1 Adenocarcinoma
21 135625 2 118600000 122100000 Gain Adenocarcinoma
22 171545 3 169200000 172500000 Gain MECOM Adenocarcinoma
23 171548 3 169200000 172500000 Gain Adenocarcinoma
24 171550 3 169200000 172500000 Gain MECOM Adenocarcinoma
25 172147 3 177300000 180600000 Gain KCNMB3 Adenocarcinoma
26 172149 3 177300000 180600000 Gain PIK3CA Adenocarcinoma
27 172225 3 178866310 178952497 Gain PIK3CA Adenocarcinoma
28 172903 3 187500000 189400000 Gain MASP1 Adenocarcinoma
29 173068 3 189400000 193800000 Gain FGF12 Adenocarcinoma
30 173072 3 189400000 193800000 Gain TP63 Adenocarcinoma
31 173431 3 193800000 199501827 Gain RUBCN Adenocarcinoma
32 173434 3 193800000 199501827 Gain Adenocarcinoma
33 173436 3 193800000 199501827 Gain Adenocarcinoma
34 173438 3 193800000 199501827 Gain Adenocarcinoma
35 173440 3 193800000 199501827 Gain Adenocarcinoma
36 173442 3 193800000 199501827 Gain OPA1 Adenocarcinoma
37 206066 6 135544145 135582003 Amplification MYB Adenocarcinoma
38 218057 7 107200000 137300000 Amplification Adenocarcinoma
39 218695 7 116312458 116438439 Copy number MET Adenocarcinoma
40 225387 7 45400000 54000000 Copy number EGFR Adenocarcinoma
41 226106 7 55054218 55242525 Amplification EGFR Adenocarcinoma
42 230093 7 97900000 104400000 Gain TRRAP Adenocarcinoma
43 230096 7 97900000 104400000 Gain ZKSCAN1 Adenocarcinoma
44 230097 7 97900000 104400000 Gain ZNF3 Adenocarcinoma
45 230098 7 97900000 104400000 Gain ZSCAN21 Adenocarcinoma
46 233908 8 128816946 128822855 Amplification MYC Adenocarcinoma
47 239383 8 38973661 39081936 Amplification ADAM9 Adenocarcinoma
48 240761 8 55041668 55097561 Translate TCEA1 Adenocarcinoma
49 241225 8 59800000 146274826 Copy number Adenocarcinoma

Expression for Adenocarcinoma

Search GEO for disease gene expression data for Adenocarcinoma.

Pathways for Adenocarcinoma

Pathways related to Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.17 TP53 SMAD4 RB1 KRAS ERBB2 EGFR
2
Show member pathways
13.87 TP53 TGFBR2 SMAD4 RB1 PIK3CA MUC1
3 13.86 TP53 TGFBR2 SMAD4 PIK3CA KRAS ERBB2
4
Show member pathways
13.86 AKT1 APC ATM BAX BRAF CDH1
5
Show member pathways
13.8 AKT1 BIRC5 BRAF CDKN2A EGFR ERBB2
6
Show member pathways
13.72 TP53 SMAD4 KRAS ERBB2 EGFR BRAF
7
Show member pathways
13.64 AKT1 BAX BRAF CDH1 EGFR ERBB2
8
Show member pathways
13.58 AKT1 APC ATM BAX BRAF CDKN2A
9
Show member pathways
13.5 TGFBR2 SMAD4 PIK3CA KRAS ERBB2 EGFR
10
Show member pathways
13.42 TGFBR2 SMAD4 KRAS ERBB2 EGFR CDH1
11
Show member pathways
13.38 AKT1 APC BRAF CDH1 EGFR ERBB2
12
Show member pathways
13.06 TP53 CDKN2A BIRC5 BAX ATM AKT1
13
Show member pathways
13.04 AKT1 BAX BIRC5 CDKN2A EGFR PIK3CA
14
Show member pathways
13 TGFBR2 PIK3CA KRAS ERBB2 EGFR BRAF
15
Show member pathways
12.97 TP53 TGFBR2 SMAD4 PIK3CA KRAS BRAF
16 12.96 AKT1 BAX BRAF EGFR ERBB2 KRAS
17
Show member pathways
12.95 PIK3CA KRAS BRAF BIRC5 AKT1
18
Show member pathways
12.94 PIK3CA KRAS EGFR BRAF AKT1
19
Show member pathways
12.93 AKT1 APC BRAF KRAS PIK3CA
20
Show member pathways
12.81 AKT1 APC BAX CDH1 CDKN2A TP53
21
Show member pathways
12.81 TP53 RB1 KRAS EGFR BRAF AKT1
22 12.81 AKT1 APC ATM BAX CDH1 CDKN2A
23
Show member pathways
12.77 KRAS EGFR CDKN2A BRAF AKT1
24
Show member pathways
12.77 TP53 RB1 PIK3CA KRAS EGFR ATM
25
Show member pathways
12.75 TP53 TGFBR2 SMAD4 RB1 PIK3CA KRAS
26
Show member pathways
12.72 AKT1 BAX BIRC5 EGFR ERBB2 KRAS
27
Show member pathways
12.6 TGFBR2 SMAD4 RB1 APC AKT1
28
Show member pathways
12.6 TP53 PIK3CA ERBB2 CDH1 BRAF BAX
29 12.57 TP53 RB1 CDH1 BIRC5 APC AKT1
30
Show member pathways
12.57 TP53 PIK3CA MUC1 KRAS ERBB2 EGFR
31 12.55 AKT1 BRAF EGFR KRAS TGFBR2 TP53
32
Show member pathways
12.54 AKT1 ATM BAX EGFR ERBB2 KRAS
33
Show member pathways
12.53 TP53 SMAD4 RB1 PIK3CA KRAS ERBB2
34
Show member pathways
12.51 TGFBR2 SMAD4 PIK3CA MUC1
35
Show member pathways
12.51 PIK3CA KRAS ERBB2 EGFR CDH1 BRAF
36
Show member pathways
12.5 PIK3CA KRAS EGFR AKT1
37
Show member pathways
12.49 AKT1 BRAF KRAS PIK3CA
38
Show member pathways
12.47 TGFBR2 SMAD4 RB1 CDKN2A
39
Show member pathways
12.46 AKT1 BAX BIRC5 TP53
40 12.43 PIK3CA ERBB2 EGFR BRAF AKT1
41
Show member pathways
12.42 PIK3CA ERBB2 EGFR AKT1
42
Show member pathways
12.4 TP53 SMAD4 RB1 CDKN2A ATM
43
Show member pathways
12.37 PIK3CA EGFR BRAF AKT1
44
Show member pathways
12.36 AKT1 BAX PIK3CA TP53
45
Show member pathways
12.36 AKT1 BRAF KRAS RB1
46
Show member pathways
12.36 AKT1 ATM BAX RB1 TP53
47 12.35 PIK3CA KRAS EGFR AKT1
48
Show member pathways
12.35 TP53 CDKN2A BAX AKT1
49
Show member pathways
12.35 PIK3CA KRAS ERBB2 EGFR
50 12.33 TP53 TGFBR2 SMAD4 PIK3CA KRAS CDH1

GO Terms for Adenocarcinoma

Biological processes related to Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.42 AKT1 BIRC5 EGFR EPCAM ERBB2 KRAS
2 protein phosphorylation GO:0006468 10.41 AKT1 ATM BIRC5 BRAF EGFR ERBB2
3 positive regulation of gene expression GO:0010628 10.35 TP53 KRAS ERBB2 CDKN2A BRAF ATM
4 regulation of apoptotic process GO:0042981 10.27 TP53 BIRC5 BAX ATM AKT1
5 negative regulation of cell growth GO:0030308 10.22 CDKN2A RB1 SMAD4 TP53
6 apoptotic process GO:0006915 10.22 TP53 TGFBR2 RB1 CDKN2A BIRC5 BAX
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.19 PIK3CA EGFR BRAF AKT1
8 Ras protein signal transduction GO:0007265 10.19 TP53 RB1 KRAS CDKN2A
9 negative regulation of cell population proliferation GO:0008285 10.17 TP53 TGFBR2 SMAD4 RB1 CDKN2A BAX
10 phosphatidylinositol 3-kinase signaling GO:0014065 10.12 PIK3CA ERBB2 AKT1
11 cellular response to epidermal growth factor stimulus GO:0071364 10.12 ERBB2 EGFR AKT1
12 ovarian follicle development GO:0001541 10.11 SMAD4 BAX ATM
13 negative regulation of neuron apoptotic process GO:0043524 10.11 BAX BIRC5 BRAF KRAS PIK3CA
14 positive regulation of protein phosphorylation GO:0001934 10.11 AKT1 BIRC5 BRAF EGFR ERBB2 KRAS
15 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 10.03 TP53 MUC1 ATM
16 gastrulation GO:0007369 10.01 TP53 TGFBR2 SMAD4
17 replicative senescence GO:0090399 10.01 ATM CDKN2A TP53
18 epidermal growth factor receptor signaling pathway GO:0007173 10.01 PIK3CA EGFR BRAF AKT1
19 cellular response to growth factor stimulus GO:0071363 10 AKT1 EGFR ERBB2 TGFBR2
20 striated muscle cell differentiation GO:0051146 9.99 RB1 KRAS AKT1
21 glial cell proliferation GO:0014009 9.97 TP53 RB1 KRAS
22 regulation of cell cycle GO:0051726 9.97 APC ATM BAX BIRC5 CDKN2A RB1
23 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.95 TP53 MUC1
24 apoptotic mitochondrial changes GO:0008637 9.95 CDKN2A BAX AKT1
25 regulation of cell population proliferation GO:0042127 9.92 TP53 TGFBR2 SMAD4 ERBB2 EGFR BRAF
26 response to UV-A GO:0070141 9.91 EGFR AKT1
27 neuron apoptotic process GO:0051402 9.91 TP53 RB1 KRAS BAX ATM
28 negative regulation of immature T cell proliferation in thymus GO:0033088 9.81 ERBB2 CDKN2A
29 regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902108 9.8 TP53 BAX
30 phosphorylation GO:0016310 9.65 TGFBR2 PIK3CA ERBB2 EGFR CDKN2A BRAF
31 cell population proliferation GO:0008283 9.28 TP53 SMAD4 RB1 KRAS EGFR BAX

Molecular functions related to Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.02 AKT1 ATM BAX BIRC5 BRAF CDH1
2 nucleotide binding GO:0000166 9.92 TGFBR2 PIK3CA KRAS ERBB2 EGFR BRAF
3 protein kinase activity GO:0004672 9.76 TGFBR2 ERBB2 EGFR BRAF ATM AKT1
4 disordered domain specific binding GO:0097718 9.65 TP53 RB1 CDKN2A
5 kinase activity GO:0016301 9.32 TGFBR2 PIK3CA ERBB2 EGFR CDKN2A BRAF

Sources for Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....